Richard Edwards' Stock Ratings

Goldman Sachs Analyst

Richard Edwards is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024

Overall Average Return

28.8%

Smart Score

75.7%

Overall Average Return Percentile

87th

Number of Ratings

3
Buy NowGet Alert
07/03/2024ONONBuy Now
On Holding
$37.8924.04%$41 → $47MaintainsBuyGet Alert
08/18/2023ONONBuy Now
On Holding
$37.890.29%$41 → $38MaintainsBuyGet Alert
11/21/2022ONONBuy Now
On Holding
$37.89-26.1%$37 → $28UpgradeNeutral → BuyGet Alert

Recent Analyst Stock Rating News

Tesla To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Wednesday
What 9 Analyst Ratings Have To Say About Edwards Lifesciences
Expert Ratings For Edwards Lifesciences
Assessing Edwards Lifesciences: Insights From 14 Financial Analysts
Deep Dive Into Edwards Lifesciences Stock: Analyst Perspectives (14 Ratings)
Cherokee Tribe Votes To Legalize Marijuana In North Carolina Despite GOP Congressman's Threats
The Eastern Band of Cherokee Indians (EBCI) in North Carolina have said yes to recreational cannabis in a Thursday referendum, making the reservation the only place in the state to legalize adult-use cannabis.
GOP Congressman's 'Stop Pot Act' Seeks To Cut Fed Funding To States & Tribes Legalizing Cannabis: Guess Who He's Targeting
As the Eastern Band of Cherokee Indians in North Carolina prepare to vote on legalizing adult-use cannabis, U.S. Rep. Chuck Edwards (R) is threatening to defund the tribe — whether the measure passes or not. The tribe's Principal Chief Richard Sneed is calling the Republican congressman’s move “a major political blunder.”
These Were The Best Performing REITs in May 2023
In any stock, exchange-traded fund (ETF) or mutual fund prospectus, an investor is likely to come across the phrase "past performance is no guarantee of future results.” You should never assume that an investment will continue to perform well just because it's done so in the past.
Pablo Escobar's 'Cocaine Hippo' Gets Killed In SUV Collision: Are Large Vehicles The Apex Predator On The Road?
West Virginia Senators Discuss Making Kratom, Delta-8 & Delta-9 Schedule 1 Drugs, Schools' New Policy On Medical Marijuana & Naloxone
The Senate Judiciary Committee in West Virginia recently approved legislation that would place kratom, delta-8, and delta-10 products as Schedule 1 drugs.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free